Synopsis: Shares of this specialty chemicals company were in focus after a brokerage highlighted its strategic shift toward high-value chemical segments, supported by expansion plans, stronger integration, and improving long-term growth visibility.
The shares of this small cap company majorly engaged in manufacturing of chemicals providing essential derivatives and specialty chemicals with commitment to sustainability, advanced manufacturing capabilities and many more were in focus after the brokerage sees x percent upside potential.
With the market capitalization of Rs. 5016 Crores, the shares of Epigral Ltd were trading at around Rs. 1163 per share which is 45 percent discount from its 52 week high of Rs. 2114 per share and is trading at a P/E of 15.2 whereas industry P/E stands at 30.7
Brokerage view
Systematix has initiated coverage on Epigral with a ‘Buy’ rating and a target price of ₹1380 implying an upside potential of around x%. The brokerage believes the company is well-positioned for long-term growth, driven by its shift towards specialty chemicals, capacity expansions in CPVC and ECH, stronger vertical integration, and improving revenue mix, which are expected to support healthier margins and earnings visibility.
Transforming Growth via Specialty Chemical Expansion
EPIGRAL is strategically shifting toward value-added derivatives and specialty chemicals—such as epichlorohydrin (ECH), CPVC, and chlorotoluene—to capitalize on strong domestic demand. Driven by vertical integration into the chlor-alkali value chain, capacity expansions, and cost efficiencies, the company targets a 70:30 revenue split favoring specialty chemicals and a >20% RoCE by FY28.
Analysts project an ~19% revenue CAGR and ~17% EBITDA CAGR over FY26–28E, initiating a BUY rating with a target price of Rs 1,380 (15x FY28E EPS). Key risks include input cost volatility, cyclical demand, competitive pressures, and material substitution.
Capturing Value Through Advanced Integration
EPIGRAL is set to unlock its next phase of growth by doubling down on high-value derivatives and specialty chemicals. Management plans to shift the business mix so that these premium products contribute ~70% of total revenue by FY28E, up from ~52% in FY26 while actively investing in new chemistries to ride broader industry tailwinds.
At the core of this transformation is its established chlor-alkali segment, which continues to act as a dependable cash cow and a guaranteed source of chlorine. By deepening its vertical integration and utilizing ~90-95% of its internal chlorine (up from ~75% today), EPIGRAL is well-positioned to strengthen operational resilience and structurally boost profitability.
Strong Cash Generation to Solidify Financial Health
EPIGRAL is well-positioned to generate a robust Rs 8.1bn in free cash flow over FY26–28E—even while funding Rs 7.4bn in ongoing capital expenditure. This strong cash engine will allow the company to systematically pay down debt and transition from a net debt to EBITDA ratio of 1.6x in FY24 to a comfortable net cash position (-0.27x) by FY28E, significantly fortifying its balance sheet.
EPIGRAL is transitioning into a resilient specialty chemicals player by deepening vertical integration, launching value-added products, and maximizing internal raw material usage. Backed by cash-generative core operations and improving cost efficiencies, the company is poised to fund its aggressive expansion while simultaneously strengthening its financial health. This strategy positions EPIGRAL for sustainable long-term profitability and market leadership, despite potential headwinds from market volatility and competition.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
